Nilotinib v 1.linii léčby pacientů s chronickou myeloidní leukemií v chronické fázi
| Title in English | Nilotinib in first-line therapy of chronic myeloid leukaemia in chronic phase |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | chronic myeloid leukaemia; tyrosine kinase inhibitors; imatinib; nilotinib; first-line therapy |
| Description | The introduction of imatinib into the therapy of chronic myeloid leukaemia (CML) resulted in dramatic change in the natural course of the disease and was associated with radical improvement in patient prognosis. The disease in a significant proportion of patients, however, is resistant to imatinib, or loses sensitivity to therapy over time. Nilotinib was developed as an imatinib derivative that exhibited higher efficacy and selectivity for BCR-ABL tyrosine kinase inhibition. It has demonstrated efficacy in patients with CML with imatinib resistance or intolerance, and having been approved for this indication in 2007 it has assumed its place in the setting of second-line therapy of patients with CML. As part of efforts to improve the outcomes in patients with CML, two dosing regimens of nilotinib were compared with imatinib in the therapy of newly diagnosed patients with CML in a randomized phase III trial, and based on significantly better outcomes in all study parameters, it was approved as first-line therapy of patients with chronic phase CML in 2010. |